CINCINNATI, Ohio, June 6 -- The University of Cincinnati posted the following news:

* * *

UC expert weighs in on current MASH treatment approaches

He says pharmacotherapy pipeline is rapidly evolving

By Megan Burgasser, burgasma@ucmail.uc.edu

As MedCentral recently reported, pending broader pharmacologic approvals for metabolic dysfunction-associated steatohepatitis (MASH), lifestyle modifications remain the go-to intervention.